Edwards' stock falls on news of US reimbursement review for Sapien
This article was originally published in Clinica
Executive Summary
News that the US Centers for Medicare and Medicaid Services (CMS) is reviewing reimbursement coverage of Edwards Lifesciences' Sapien heart valve system – which could lead to limited uptake of the technology if a negative conclusion is reached – has led nervous investors to drive down the company's share price. The agency expects to complete its review by 26 June 2012.